Introduction
The novel coronavirus disease, known as coronavirus disease 2019 (COVID-19), is an acute infectious respiratory disease that first emerged in Wuhan, China, in late 2019 and is characterized as a pandemic in mid-March 2020 by World Health Organization [1]. It has been found that COVID-19 causes severe acute respiratory syndrome (SARS, therefore coined as SARS-CoV-2) similar to two other RNA viruses from the Coronoviridea family SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV). SARS-CoV-2 main route of entry to a human host is the angiotensin-converting enzyme 2 (ACE2) receptor. ACE2 receptor is ubiquitously expressed on the surfaces of various cell types, including cells of the airway epithelium which is the major site of infection [2]. Besides the ACE2 receptor, SARS-CoV-2 uses the transmembrane serine protease 2 (TMPRSS2), a cellular serine protease, for the host cell entry, which activates the SARS-CoV-2 spike protein by cleaving the Furin site at the S1/S2 subunits [3, 4]. Upon entry, the virus can subsequently affect endosomes, and eventually, fuse viral and lysosomal membranes [5]. Coronaviruses are pathogens affecting both humans and animals; particularly SARS-CoV-2 is highly contagious and can be transmitted directly through respiratory droplets often even before the infected person shows symptoms or indirectly by touching infected surfaces and following inoculation within mucosal layers [2, 6].
SARS-CoV-2 infection results in the development of an unusual form of pneumonia and can cause acute respiratory distress syndrome (ARDS) [7]. More than 35 million infected cases were diagnosed worldwide, with a mortality rate of 4% (1–20%) and about 20% of those who get COVID-19 become seriously ill and require oxygen, with 5% becoming critically ill and needing intensive care (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19), mainly in old patients with multiple comorbidities. Of note, it is estimated that life-threatening conditions may be observed in less than 1:1000 infected individuals below the age of 50 [7], suggesting some underlying susceptibility factors in this selected group of patients. Hence, it is expected to see severe COVID-19 cases in individuals with primary immunodeficiencies (PIDs). Due to poor cellular immunity and viral control, disease severity is expected to be higher in combined immunodeficiencies than patients with humoral defects. Patients with immune dysregulation may also be vulnerable to the disease because of the risk of an adverse unregulated inflammatory response in these patients. Noteworthy, patients with defects in their innate immune system, especially those with defects in the interferon (IFN) pathway, seem to face more frequently a critical course of the disease [8]. PID prevalence (range 1:8500–1:100000 for symptomatic patients) and the proportion of PID entities (more than 400 heterogeneous defects) in each country may impact the number of patients at risk due to COVID-19. Recent discoveries identified the role of defective immune-related genes involved in RNA-virus infection susceptibilities with a critical function in IFN pathways including IFN receptors (IFNAR1 and IFNAR2), signal transducer and activator of transcription of IFN (STAT1 and STAT2), IFN regulatory factors (IRF7, IRF9, and IFIH1), and RNA polymerase III (POLR3A, POLR3C, and POLR3F) [9].
Anzeige
To investigate this hypothesis, we conducted a prospective study to compare the rate and outcomes of COVID-19 infection between diagnosed cases in the Iranian PID registry with population-based data.
Methods
Iranian Primary Immunodeficiency Registry (IPIDR)
This study was conducted as a cohort of patients, prospectively enrolled in the IPIDR from the “National PID Network” [10]. The IPIDR is managed by the Research Center for Immunodeficiencies (Tehran, Iran) and its main aim is to provide epidemiological, clinical, and molecular data of PID in Iran. By the latest estimation in 2020, Iran has a population of 84,012,442 citizens (with an average annual birth rate of 1,300,000) and according to the age structure, 23.7% are less than 14 years old. Data on COVID-19 infection in PID patients were compared with the normal population (471,772 patients, incidence of 2036 cases per day, 26,957 total death, https://www.worldometers.info/coronavirus/, reported from Iranian Ministry of Health, Tehran, Iran, access data 4 October 2020). This study received approval from the Ethics Committee of the Tehran University of Medical Science. Moreover, written informed consent has been obtained from all patients, their parents, or legal guardians.
The registry database is hosted in the Children’s Medical Center (Tehran, Iran) which serves as a referral hospital for suspected or diagnosed PID cases. Moreover, 38 medical centers, affiliated to 27 medical science universities, collaborated in the registry program from the major provinces of the country to form the PID network. All participating centers had access to national guidelines [11] and necessary laboratory equipment for clinical and immunological evaluations [10]. Subsequently, cases with a suspected diagnosis were referred and re-evaluated in the Children’s Medical Center for a definitive diagnosis.
Clinical and Immunologic Diagnoses in COVID-19-Infected PID Patients
The clinical diagnosis of the PID patients was made according to the criteria of the European Society for immunodeficiencies (ESID) [12]. A questionnaire surveyed the patients’ demographic information, age of disease onset, age of diagnosis, family history, a detailed clinical history that included vaccination history and associated adverse reactions, recurrent infections, physical examination findings, laboratory data, and treatment history. Secondary defects of the immune system, including those caused by human immunodeficiency virus (HIV) were ruled out. Laboratory evaluations were performed in the study group as indicated, including complete blood and differential counts, serum protein profile and immunoglobulin levels, serum IgG subclass levels, isohemagglutinin titers, specific antibody responses, disease-specific autoantibody measurements, flow cytometric evaluation of lymphocyte subsets, nitro blue tetrazolium dye/dihydrorhodamine test, granulocyte function and chemotaxis tests, lymphocyte transformation and T cell function tests, radiosensitivity, measurement of complement component levels, and hemolytic complement activity [10]. Microbiological, pathological and imaging evaluations were performed for clinical diagnosis when required. A computerized database program (new registry section in http://rcid.tums.ac.ir/, access data 4 October 2020) was implemented for data entry. After reviewing the cases by the administrator of the system for duplicated cases, patients with incomplete diagnostic criteria were excluded. The online database was updated frequently for approved patients and all follow-up data sent by the end of the study period were included. If the diagnosis of PID were confirmed before the time of COVID-19 patients, following evaluation were performed including new clinical presentation, high-resolution computed tomography (HRCT), and reverse transcriptase-polymerase chain reactions (RT-PCR) as well as complete blood count (CBC), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). For patients with a recent diagnosis of PID, a comprehensive questionnaire was provided and filled out for each patient which consists of demographical data, clinical manifestations related to their PID and COVID-19, laboratory tests findings such covering both PID and COVID-19 diagnoses confirmation. Furthermore, the type of treatment and outcome were also provided for each patient.
Anzeige
Genetic Analysis and Diagnoses in COVID-19-Infected PID Patients
Genomic DNA was extracted from whole blood from patients who agreed with genetic tests and for patients with classical clinical presentations suggestive of a specific PID, targeted sequencing was performed (Table S1). For patients in whom targeted sequencing failed or who had a clinical presentation resembling several genetic defects, whole-exome sequencing was performed to detect single nucleotide variants, insertion/deletions, and large deletions using a pipeline described previously [13, 14]. Candidate variants were evaluated by the Combined Annotation Dependent Depletion (CADD) algorithm and an individual gene cutoff given by using the Mutation Significance Cutoff (MSC) was considered for impact predictions [15]. The Gene Damage Index (GDI) server and the Human Gene Connectome (HGC) were used to making a combined effect prediction [15]. The pathogenicity of all disease attributable gene variants was re-evaluated using the updated guideline for interpretation of molecular sequencing by the American College of Medical Genetics and Genomics criteria [16, 17], considering the allele frequency in the population database, computational data, immunological data, familial segregation and parental data (confirmatory Sanger sequencing for probands and their parents), and clinical phenotyping.
Classification of COVID-19-Infected PID Patients
After confirmation of their clinical and genetic diagnosis, patients were classified according to the International Union of Immunological Societies (IUIS) updated classification including 9 categories of immunodeficiencies affecting cellular and humoral immunity (non-syndromic combined immunodeficiency or CID), combined immunodeficiencies with associated or syndromic features (syndromic CID), predominantly antibody deficiencies (PAD), diseases of immune dysregulation, congenital defects of phagocyte number or function (phagocytic disorders), autoinflammatory disorders, defects in intrinsic and innate immunity, complement deficiencies, and phenocopies of inborn errors of immunity [9].
Results
Among 4718 registered patients, 2754 patients (998 females, median age 108 months) were alive and on monthly follow-up (58.3%, before the emergence of COVID-19 first report in the country 19 February 2020). During this period, each patient had on average 8 follow-up visits in our peripheral centers, and the COVID-19 test was performed in patients with the clinical triad of cough, fever, and dyspnea. To date, 19 patients (7 females, median age 106 months) were confirmed with positive reverse transcriptase-polymerase chain reactions (RT-PCR) SARS-CoV-2 test (1:144 incidence compared to 1:178 in the total population, 1.23 folds higher risk of infections). It seems that this measurement is underestimated since PID patients/families were trained for tight isolation compared to other immunocompetent individuals in the population. Exposure to SARS-CoV-2 from an unknown source or a source outside the child’s family accounted for 84.2% of the cases of infection (15.8% of PID patients have a medical history of exposure to another COVID-19-infected family members prior to their hospital admission). Detailed comparison of infection rates between PID patients versus the total population based on adjusted age-groups is shown in Fig. S1.
Combined immunodeficiencies (n = 10, all without hematopoietic stem cell transplantation or HSCT, 47.0%) were the major PID entity among COVID-19 positive cases followed by humoral immunodeficiencies (n = 4), phagocytic defects (n = 2), immune dysregulation (n = 2), and autoinflammatory disorders (n = 1, Table 1). Of note, no COVID-19 infection was observed in patients with innate or complement deficiencies (117 and 85 total registered alive patients, respectively). COVID-19 infections alone or in complex with other manifestations were the first clinical presentation of PID in 4 patients, mainly combined immunodeficiencies (Tables 2 and 3). Current genetic data on the evaluated patients is indicated in Fig. S2. Of note, COVID-19 infection was not yet reported in any of the alive patients with a defect in the IFN pathway (n = 23, data not shown). The geographical distribution of identified patients matched with the cumulative incidence of PID, but not with the incidence of COVID-19 in the general population (Fig. S3).
Table 1
Epidemiologic characteristics, genetic diagnosis and outcomes of COVID-19 infection in the patients with different types of primary immunodeficiencies
Primary immunodeficiency categories | Total patients in the registry | Alive patients during the pandemic | Number of COVID-19 patients (%) | Monogenic defects of patients with COVID-19 | Mortality due to COVID-19, N (%) | Mortality rate due to COVID-19 |
|---|---|---|---|---|---|---|
Combined immunodeficiencies | 1392 | 630 | 10 (1.5) | – | 6 (60.0) | 0.009 |
Non-syndromic combined immunodeficiencies | 576 | 247 | 6 (2.4) | – | 5 (83.3) | 0.020 |
Severe combined immunodeficiency | 355 | 113 | 5 (4.4) | – | 4 (80) | 0.035 |
Less profound combined immunodeficiencies | 221 | 134 | 1 (0.7) | STK4 | 1 (100) | 0.007 |
Syndromic combined immunodeficiencies | 816 | 383 | 4 (1.0) | – | 1(25) | 0.002 |
Wiskott-Aldrich syndrome | 74 | 59 | 1 (1.7) | WAS | – | – |
Ataxia-telangiectasia | 292 | 86 | 1 (1.1) | ATM | – | – |
Other syndromic combined immunodeficiencies | 450 | 238 | 2 (0.8) | DNMT3B (n = 2) | 1 (50) | 0.004 |
Predominantly antibody deficiencies | 1391 | 1002 | 4 (0.4) | – | – | – |
Agammaglobulinemia | 208 | 147 | 1 (0.6) | BTK | – | – |
Common variable immunodeficiency | 599 | 352 | 1 (0.2) | – | – | – |
Hyper immunoglobulin M syndrome | 102 | 86 | 1 (1.1) | – | – | – |
Selective IgA deficiency | 193 | 185 | 1 (0.1) | – | – | – |
Other antibody deficiencies | 285 | 232 | 0 | – | – | – |
Congenital defects of phagocytes | 782 | 426 | 2 (0.4) | – | – | – |
Chronic granulomatous disease | 385 | 217 | 2 (0.9) | CYBA (n = 1) | – | – |
Other phagocytosis defects | 397 | 209 | 0 | – | – | – |
Diseases of immune dysregulation | 117 | 90 | 2 (2.2) | – | 1 (50) | 0.011 |
Familial hemophagocytic lymphohistiocytosis | 44 | 37 | 1 (2.7) | RAB27A | 1 (100) | 0.027 |
Susceptibility to EBV and lymphoproliferation | 50 | 34 | 1 (2.9) | CD70 | – | – |
Other immune dysregulations | 23 | 19 | 0 | – | – | – |
Autoinflammatory disorders | 734 | 389 | 1 (0.2) | – | 1 (100) | 0.002 |
Non-inflammasome-related conditions | 45 | 40 | 1 | IL1RN | 1 (100) | 0.025 |
Other autoinflammatory disorders | 689 | 549 | 0 | – | – | – |
Other primary immunodeficiencies* | 302 | 217 | 0 | – | – | – |
Total | 4718 | 2754 | 19 (0.68) | – | 8 (42.1) | 0.003 |
Table 2
Demographic data and clinical manifestation before COVID-19 infections in 19 primary immunodeficient patients
Primary immunodeficiency categories | ID | PID diagnosis | Gender | Age of onset (m) | Age of PID diagnosis (m) | Infection | Autoimmunity | Lymphoproliferation | Other PID clinical manifestation | |
|---|---|---|---|---|---|---|---|---|---|---|
Combined immunodeficiencies | Non-syndromic combined immunodeficiencies | P1 | SCID | F | 1 | 1 | URI, LRI | – | LAP | Sensitivity to light |
P2 | SCID | M | 6 | 20 | LRI | – | – | – | ||
P3 | SCID | M | 6 | 6 | LRI | – | – | – | ||
P4 | Omenn syndrome | M | 1.5 | 2.5 | BCGosis, LRI | – | LAP | Severe scaling erythematous skin lesions | ||
P5 | CID | M | 4 | 11 | LRI | AIT | LAP | – | ||
P6 | STK4 | M | 108 | 108 | Meningitis, cellulitis | ITP, AIHA | LAP | Seizure, neurological disorders | ||
Syndromic combined immunodeficiencies | P7 | WAS | M | 4 | 4 | LRI | – | – | Chronic diarrhea, microcytic thrombocytopenia | |
P8 | ATM | M | 24 | 108 | URI, LRI | – | – | Ataxic gait, telangiectasia | ||
P18 | DNMT3B | M | 10 | 17 | URI, LRI | – | LAP | Recurrent diarrhea | ||
P19 | DNMT3B | F | 15 | 28 | URI, LRI | – | – | Recurrent diarrhea, bronchiectasis | ||
Predominantly antibody deficiencies | P9 | BTK | M | 36 | 48 | Skin infection, URI, LRI | – | – | Urticaria, erythematous skin lesions | |
P10 | CVID | M | 12 | 240 | OME, LRI | ITP, AIHA, JIA | – | Recurrent diarrhea, bronchiectasis | ||
P11 | HIgM | F | 36 | 72 | OME, LRI, osteomyelitis | – | HSM | FTT, granulomatous inflammatory process in BM | ||
P12 | SIgAD | M | 6 | 84 | OME, LRI, recurrent oral herpes lesions | – | – | Bronchiectasis | ||
Congenital defects of phagocytes | P13 | CGD | F | 36 | 36 | LRI | – | – | FTT | |
P14 | CYBA | M | 1 | 120 | URI, LRI | – | Pulmonary granulomatosis lesion | Bronchiectasis severe pulmonary fibrosis | ||
Diseases of immune dysregulation | P15 | RAB27A | F | 60 | 106 | URI, LRI | AIHA | HSM | Albinism, gray hair, severe anal ulcer, hemophagocytic BM | |
P16 | CD70 | F | 84 | 108 | URI, LRI | Behcet’s disease, alopecia | HSM | HL | ||
Autoinflammatory disorders | P17 | IL1RN | F | 1 | 4 | Cellulitis, dental abscess, gingivitis | UC | HSM | Rash and skin lesions, edema in the right shoulder, chronic diarrhea, severe generalized erythroderma, ascites, anemia, femur swelling | |
Table 3
Clinical presentation after COVID-19 infections and outcome of treatment strategy in 19 primary immunodeficient patients
Primary immunodeficiency categories | ID | PID diagnosis | Age at COVID − 19 infection (m) | Clinical signs and complications after COVID-19 | Organ involvement | Treatment strategy | Medications | Outcome | |
|---|---|---|---|---|---|---|---|---|---|
Combined immunodeficiencies | Non-syndromic combined immunodeficiencies | P1 | SCID | 10 | Fever, cough, drop of oxygen saturation, respiratory distress | Lung | Hospitalized, NICU, requiring O2/NIV | Azithromycin, IVIG | Death |
P2 | SCID | 20 | Drop of oxygen saturation | Lung | Hospitalized, NICU | Azithromycin, IVIG | Death | ||
P3 | SCID | 8 | Fever, faintness, respiratory distress | Lung | Hospitalized, NICU | Hydroxychloroquine, vancomycin, meropenem, IVIG | Death | ||
P4 | Omenn syndrome | 6 | Fever, tachypnea, vomiting heart failure, seizure(once), cardiomegaly, a drop of oxygen saturation, respiratory distress | Heart, Lung | Hospitalized, NICU | Isoniazid, rifampin, ethambutol, vitamin B6, cotrimoxazole | Death | ||
P5 | CID | 11 | Respiratory distress, CD4 lymphopenia | Lung | Hospitalized, NICU | Hydroxychloroquine, azithromycin, IVIG | Recovery | ||
P6 | STK4 | 144 | Fever, loss of appetite, jaundice, abdominal pain, bloody diarrhea, cardiac and pulmonary arrest | Gastrointestinal, lung, heart | Hospitalized, requiring O2/NIV | Acyclovir, ceftriaxone, vancomycin, dexamethasone | Death | ||
Syndromic combined immunodeficiencies | P7 | WAS | 5 | Fever, cough, respiratory distress | Lung | Hospitalized requiring O2/NIV | Meropenem. cotrimoxazole, vancomycin, azithromycin, IVIG | Recovery | |
P8 | ATM | 206 | Fever, diarrhea | Gastrointestinal | Hospitalized | Azithromycin, IVIG | Recovery | ||
P18 | DNMT3B | 130 | Fever, cough, respiratory distress | Lung | Hospitalized requiring O2/NIV | Azithromycin, IVIG | Recovery | ||
P19 | DNMT3B | 152 | Fever, dry coughs, loss of appetite, vomiting, seizure, loss of awareness, respiratory distress | Lung, gastrointestinal | Hospitalized, ICU | Azithromycin, ceftriaxone, vancomycin, IVIG | Death | ||
Predominantly antibody deficiencies | P9 | BTK | 430 | Dry cough, fever, sweating, abdominal pain, wheezing | Gastrointestinal, lung | Hospitalized, requiring O2/NIV | Azithromycin, IVIG | Recovery | |
P10 | CVID | 444 | Fever, dry cough, fatigue, shortness of breath, muscular pain, chest pain | Lung | Hospitalized | Hydroxychloroquine, azithromycin, meropenem, IVIG | Recovery | ||
P11 | HIgM | 72 | Fever, cough | Lung | Hospitalized, requiring O2/NIV | Hydroxychloroquine, azithromycin | Recovery | ||
P12 | SIgAD | 96 | Fever, mild clear rhinorrhea, mild suprasternal retraction, tachypnea, mild consolidation, productive cough, clear rhinorrhea | Lung | Hospitalized | Meropenem, clindamycin, hydroxychloroquine, IVIG | Recovery | ||
Congenital defects of phagocytes | P13 | CGD | 108 | Fever, cough, headache | Lung | Hospitalized, requiring O2/NIV | Cotrimoxazole, cefixime, meropenem, vancomycin | Recovery | |
P14 | CYBA | 216 | Respiratory distress, fatigue, dry cough, fever, headache, loss of sense of smell and hearing, eyelid edema, severe cardiac enlargement | Lung, olfactory and auditory, cardiovascular system | Hospitalized | Cotrimoxazole, hydroxychloroquine | Recovery | ||
Diseases of immune dysregulation | P15 | RAB27A | 106 | Fever, vomiting, HM, liver involvement and pitting edema, respiratory distress | Gastrointestinal | Hospitalized, ICU | Hydroxychloroquine, azithromycin | Death | |
P16 | CD70 | 372 | Fatigue, dry cough, sore throat | Lung | Hospitalized, requiring O2/NIV | Hydroxychloroquine, azithromycin, IVIG | Recovery | ||
Autoinflammatory disorders | P17 | IL1RN | 96 | Fever, dry coughs, loss of appetite, vomiting, seizure, loss of awareness, respiratory distress | Lung, gastrointestinal | Hospitalized, ICU | Hydroxychloroquine, azithromycin | Death | |
Details of clinical manifestations and laboratory findings of patients before and after SARS-CoV-2 infections are summarized in Tables 2 and 3, S2 and S3. The majority of patients had a history of lower respiratory tract infection before COVID-19 (89.4%, except for two patients with STK4 and IL1RN deficiencies). Severe distress requiring respiratory support was documented as COVID-19 features in 10 patients from which 7 had lymphoproliferation (70%) including lymphadenopathy, hepatosplenomegaly, and non-necrotizing granulomatous inflammation. Moreover, bronchiectasis (21.0%), cardiovascular complications (10.5%), and liver failure (10.5%) were observed in patients with poor prognosis. Of note, bone marrow analysis and laboratory data of COVID-19-infected patients with immune dysregulation (P15 and P16) did not reveal hemophagocytic lymphohistiocytosis (HLH) activity at the time of the current study. Acute-phase reactant proteins were negative in 8 patients, particularly in patients with severe combined immunodeficiency (SCID) and phagocytosis defects. Imaging findings on COVID-19 pulmonary complications of PID patients varied from mild prominence of bronchovascular markings to mucus plugging, prebronchial thickening, diffuse patchy opacities, collapse/consolidations, mosaic perfusion, and ground glass interstitial disease, mirroring of the severity of diagnosed PID (Figs. S4–S15).
Among the identified PID cases with COVID-19, 8 patients deceased (42.1%, Table 1) indicating a 10-folds higher mortality rate in PID patients compared to the population (0.003 vs. 0.0003, p < 0.001). Of note, the most lethal COVID-19 infection among PID entities was observed in patients with SCID (0.03) and familial hemophagocytic lymphohistiocytosis (FHL, 0.027). This notion confirms the previous hypothesis that SARS-CoV-2 are more life-threatening among patient with cellular immunodeficiency and immune dysregulation with almost 150-folds higher risk of mortality. All infected patients with less profound combined immunodeficiencies, FHL, and autoinflammatory disorders succumbed to COVID-infection. Monthly intravenous immunoglobulin replacement therapy was continued during the COVID-19 infection period in 12 patients, of which 66.6% recovered from the infection (4 deceased patients had combined immunodeficiencies, Table 2).
Discussion
The current knowledge about COVID-19 in cases with underlying immunodeficiency is scarce [18‐24]. Comparing to previous data reported mainly primary antibody deficient and male patients with COVID-19 infection (Table S4), we did not observe the dominancy of infected patients in this PID category despite their high frequency among the national registry with no deceased patient. In the first observation in 7 cases from Italy, all were antibody-deficient patients with 14.2% mortality [25]. In another report from 582 children and adolescents in Europe with PCR-confirmed SARS-CoV-2 infection, 3 patients (0.5% of total cases) had a previously diagnosed PID comprising common variable immunodeficiency, congenital neutropenia, and Schimke immuno-osseous dysplasia [26].
These data resembling the findings of the recent study by Parri et al. [27] where they highlighted immunological complications may underlie 7.4–12.5% of COVID-19 patients reported from pediatric emergency departments. However, our study may strengthen the current understanding of the impact of the pandemic on all subgroups of PID and highlights the requirement of tight measurements in children affected mainly with combined immunodeficiency and immune dysregulation. Of note, several recent studies identified that lymphopenia with prominent decreased T cell (mainly CD8+ cytotoxic T cell) counts are associated with severe COVID-19 condition and mortality [3, 28‐31]. Indeed, lymphopenia seems to correlate with the cytokine profile of the severe patients which resemble our observation in PID patients [30, 32]. On the other hand, the recent multinational cohort reported by ESID (94 patients, 37% were with mild symptoms or asymptomatic, 9.5% mortality) revealed that older patients with combined immunodeficiency (14 patients in this cohort all recovered, Table S4) manifested milder presentations compared to our patients, which may reflect different underlying diseases, but also access to optimal treatment mainly HSCT [33].
Anzeige
While the induction of effective cellular immunity is likely essential for the COVID-19 control, dysregulated T cell activation (by overproduction of IFN associated cytokines promoting retention of lymphocytes in lymphoid organs) may underly main immunopathology and contribute to disease severity in COVID-19 patients [32, 34‐36]. Although the exposure to pathogens may be lower in PID patients due to more strict self-isolation, it should be noted that the majority of PID cases require to visit the hospital and medical centers regularly which may predispose them even more to exposure to different pathogens as well as COVID-19. Even though our approach between PID patients and the general population were similarly based on decided national COVID-19 protocols (RT-PCR test was performed in cases with a suggestive triad of fever, cough, and dyspnea), it should be declared that some infected cases from the population may be missed with this inclusion criteria. Indeed, PID patients are followed-up more regularly, whereas the infected immunocompetent individual with mild infections in the normal population may not refer to the medical centers. Therefore, future epidemiological studies in other countries are required to evaluate this notion.
Our current genetic findings suggest a higher mortality rate on special molecular defects associated with deficiency of the IL-1 receptor (DIRA deficiency), STK4 deficiency (combined immunodeficiency), and RAB27A deficiency (diseases of immune dysregulation) with COVID-19. However, this data need to be supported with future evidence from other PID cohorts worldwide since these disorders are extremely rare. The notion observed could alert physicians on whether the usage of IL-1 inhibitors, such as anakinra, might be helpful for the treatment of COVID-19, and this decision should be made individually for each patient based on their genetic diagnosis and medical condition [37]. Although admission to IL-1 inhibitor in intensive care unit admitted cases could significantly reduce the mortality rate (hazard ratio of 0.22 compared to non-receivers), this might only be indicated in patients with hemophagocytic lymphohistiocytosis, macrophage activation syndrome with certain overactivation of inflammasome pathway. Of note, recent genetic analysis of 4 young brother pairs (range, 21–32 years) with respiratory insufficiency due to severe COVID-19 suggested TLR7 deficiency with reduced production of IFN-γ, a type II IFN as the underlying cause [38]. Moreover, review literature [25, 33, 38, 39, 40, 41] on PID patients with COVID-19 infections might also indicate a possible association of the disease with mutations in BTK (9 patients), IRF7 (7 patients) and TLR4 (4 patients), genes (Table S4). Although we did not identify COVID-19 infection in any of our patients with innate immune defects, this observation may also indicate future follow-up on patients with defects in TLR and IFN pathways are required to understand the genetic predisposition and pathogenesis of COVID-19 correctly, as 23 patients with disease-causing variants and life-threatening COVID-19 have been reported recently [39].
Our findings showed that about 30% of the total Iranian population is younger than 20 years and indeed it has been evident that they presented a very low frequency of COVID-19 infections and almost no mortality compared to other age categories (Fig. S1). Whereas about 57% of PID patients are under the age of 20, and a significant number of COVID-19-infected patients were observed in this age group, and the majority of them died which indicates an obvious contrast to the population. Moreover, in the total population, 70% are over 20 years old comprising a considerable percentage of patients with SARS-CoV-2 infection and the highest COVID-19 mortality. In contrast, although about 43% of PID patients are older than 20 years (1184 patients), only three SARS-CoV-2 positive patients were recorded and none of them had died due to SARS-CoV-2 which is again markedly different from the normal population. We actually observed a 10-fold higher mortality rate and a reverse pattern of the age-structure in COVID-19-infected PID patients compared to the population. This is also indeed higher than the mortality rate documented in children and adolescents in Europe where only 4 patients died, all older than 10 years, with a crude fatality rate of 0.0069. Of note, one of those deceased patients (25%) had underlying immunodeficiency due to HSCT [26]. But it is important to highlight that recessive forms of PID might play a role in the difference observed between our PID study and the European pediatric cohort since these severe PIDs may possibly increase the incidence of more severe COVID19 cases during childhood.
Conclusion
Although COVID-19 is generally a mild disease in children and adolescents (due to the low ACE2 receptor expression and functional adaptive immunity) [42, 43], a fraction of them including PID patients may develop severe disease requiring intensive unit care admission and even fatal outcome. Future studies may corroborate the individual risk of different PID disorders and clarify the potential need for preemptive measures for specific subsets of PID patients at high risk of a critical course of COVID19.
Anzeige
Compliance with Ethical Standards
Conflict of Interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending or royalties.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.